Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG―0803)

Author

WU, Y.-L¹ ; ZHOU, C² ; YANG, J.-J¹ ; CHENG, Y³ ; LU, S⁴ ; CHEN, G.-Y⁵ ; HUANG, C⁶ ; HUANG, Y.-S¹ ; YAN, H.-H¹ ; REN, S² ; LIU, Y³
[1] Guangdong Lung Cancer Institute, Guangdong General Hospital and Guandong Academy of Medical Sciences, Guangzhou, China
[2] Shanghai Pulmonary Hospital, Shanghai, China
[3] Jilin Tumor Hospital, Changchun, China
[4] Shanghai Chest Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
[5] The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China
[6] Fujian Tumor Hospital, Fuzhou, China

Source

Annals of oncology. 2013, Vol 24, Num 4, pp 993-999, 7 p ; ref : 36 ref

ISSN

0923-7534

Scientific domain

Medical oncology; Pharmacology drugs

Publisher

Oxford University Press, Oxford

Publication country

United Kingdom

Document type

Article

Language

English

Author keyword

brain metastases carcinoma erlotinib non-small-cell lung phase II clinical trial second-line therapy

Keyword (fr)

Anticancéreux Asymptomatique Cancer du cerveau Cancer du poumon Carcinome non petite cellule bronchopulmonaire Cellule Erlotinib Essai clinique phase II Homme In vitro Malade Poumon Stade avancé Traitement de deuxième intention Anti-EGFR Inhibiteur de la tyrosine kinase de l'EGFR Métastase cérébrale Appareil respiratoire Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie de l'encéphale Pathologie des bronches Pathologie des poumons Pathologie du système nerveux central Pathologie du système nerveux Protein-tyrosine kinase Transferases Tumeur maligne

Keyword (en)

Antineoplastic agent Asymptomatic Brain cancer Lung cancer non-small cell lung carcinoma Cell Erlotinib Phase II trial Human In vitro Patient Lung Advanced stage Second line treatment Cerebral metastasis Respiratory system Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Cerebral disorder Bronchus disease Lung disease Central nervous system disease Nervous system diseases Protein-tyrosine kinase Transferases Malignant tumor

Keyword (es)

Anticanceroso Asintomático Cáncer cerebro Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Célula Erlotinib Ensayo clínico fase II Hombre In vitro Enfermo Pulmón Estadio avanzado Tratamiento de segunda línea Metástasis cerebral Aparato respiratorio Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Encéfalo patología Bronquio patología Pulmón patología Sistema nervosio central patología Sistema nervioso patología Protein-tyrosine kinase Transferases Tumor maligno

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17E Tumors of the nervous system. Phacomatoses

Discipline

Neurology Pharmacological treatments Pulmonology

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

27179669

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS